Mary Kerr

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ.

Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom.

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.

Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA.

Cutfield Freeman & Co. Ltd. provides independent advice on mining finance such as joint ventures, project finance, mergers and acquisitions, private fund raising, and corporate restructuring. The firm also develops and implements strategies to address complex mining finance challenges. The company was founded in 2000 and is headquartered in London, the United Kingdom.

Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom.

Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the private company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999.

Part of AstraZeneca PLC, Mogen International Nv is a Dutch company that specializes in medicinal chemicals and botanical products. The private company is based in Leiden, the Netherlands. Mogen International was acquired by Zeneca Group Plc on May 01, 1997 for $74.96 million.

Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom.

Contura Ltd. specializes in the distribution and sale of healthcare products, both in pharmaceuticals and medical devices. The firm focuses in the fields of urology and urogynaecology. Its products include bulkamid, cystistat, and aquamid. The company was founded by Henry Geoffrey McMillan in 2000 and is headquartered in London, the United Kingdom.

Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC.

Roche Molecular Systems, Inc. develops and produces molecular-based diagnostic tests and automated testing platforms. It specializes in oncology, virology, microbiology and blood screening tests areas. The firm's customers include researchers, physicians, patients, hospitals, laboratories and blood banks. The company is headquartered in Pleasanton, CA.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

Avila Therapeutics, Inc. researches and develops covalent drugs. The company was founded in 2007 and is headquartered in Summit, NJ.

Part of Roche Holding AG, Roche Diagnostics KK is a Japanese company that manufactures and sells medical equipment. The private company is based in Tokyo, Japan. The company was founded in 1932. The CEO is Shin Ogasawara.

Roche Diagnostics A/S provides diagnostic solutions. The company is headquartered in Hvidovre, Denmark.

Part of Roche Holding AG, Roche Pharma (Schweiz) AG is a Swiss pharmaceutical company that develops innovative medicines in key therapeutic areas. The private company is based in Basel, Switzerland. The company translates scientific excellence into advanced medicines that help patients.

Nicoventures Trading Ltd. researches, develops, manufactures and delivers tobacco harm reduction products and services. The firm provides innovative and sustainable solutions to global problems arising from smoking and smoking-related illnesses. The company develops ortfolio of products and services focused on smoking cessation and harm reduction, including user-friendly nicotine delivery systems and patient-focused smoking cessation and support services. The company was founded by Christopher John Lord and David Thomas Newns in September 2008 and is headquartered in Manchester, the United Kingdom.

Flatiron Health, Inc. develops health care technology. Its OncologyCloud platform allows cancer centers, physicians and life science companies to gain actionable insights from clinical, practice management and billing data. The firm's software platform accelerates personalized medicine and research by applying advanced analytics to electronic patient care data documented by physicians. The company was founded by Nathaniel S. Turner and Zachary W. Weinberg in 2012 and is headquartered in New York, NY.

VitalneXt BV develops retails and manufactures products for healthy ageing. Its products include promanna, vital01 and other products. The firm develops products with evidence-based health benefits for the ageing population. It also develops new, proprietary, technologies, ingredients and products through its own network and through collaborations with the company's research partners. The company was founded by Rein Strijker in May 2013 and is headquartered in Amersfoort, the Netherlands.

Mimetas BV develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. It develops microfluidics-based culture plates that enable culturing and screening of a range of 3D organ and tissue models. The firm offers OrganoPlates microfluidics-based culture plates that serve as early stage screening models predicting toxic side effects and drug efficacy. The company was founded by Paul Vulto and Jos Joore in 2013 and is headquartered in Leiden, the Netherlands.

GMP-Orphan SA engages in the research and development in biotechnology. It focuses on developing and designing drugs for life-threatening and rare diseases. The company was founded by Frederic Marin on July 18, 2011 and is headquartered in Paris, France.

Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA.

Part of Roche Holding AG, Shanghai Roche Pharmaceuticals Ltd. is a Chinese company that develops, manufactures, and distributes anti-cancer and virus drugs. The private company is based in Shenchang, China.

Fibrocor Therapeutics LP is a privately held Canadian drug discovery company that is pioneering the use of tissue-specific therapeutics in the field of precision medicine, particularly in fibrosis. The company is based in Toronto, Canada. The company aims to improve the lives of patients by delivering transformative treatments that tackle the root causes of fibrosis, leading to better outcomes and enhanced quality of life. Fibrocor leverages its extensive expertise and one of the largest patient-derived clinically annotated biorepositories of fibrotic tissue to refine and validate therapeutic candidates, ensuring they meet the highest standards of efficacy and safety.